Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NING S YANG

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1275809675
CMS profile
2782337
Location
GREELEY, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$57,085.34

294 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NING S YANG

NPI 1275809675 · CMS profile ID 2782337

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

GREELEY, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275809675?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NING S YANG, NPI 1275809675, CMS profile ID 2782337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275809675?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NING S YANG, NPI 1275809675, CMS profile ID 2782337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275809675?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NING S YANG, NPI 1275809675, CMS profile ID 2782337, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1275809675?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

294 matching records · $57,085.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 294 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 294.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $35.0006/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202961366 CMS
Alexion Pharmaceuticals, Inc. $35.7206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202967050 CMS
Alexion Pharmaceuticals, Inc. $296.9706/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202969052 CMS
Alexion Pharmaceuticals, Inc. $14.1906/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202969388 CMS
Alexion Pharmaceuticals, Inc. $14.1906/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202969716 CMS
Alexion Pharmaceuticals, Inc. $86.6606/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202970524 CMS
Alexion Pharmaceuticals, Inc. $16.8306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202971628 CMS
Alexion Pharmaceuticals, Inc. $124.1306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202971706 CMS
Alexion Pharmaceuticals, Inc. $23.2006/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202974074 CMS
Alexion Pharmaceuticals, Inc. $296.9706/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202988639 CMS
TG Therapeutics, Inc. $29.7906/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226206371 CMS
ABBVIE INC. $24.2806/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204810624 CMS
SK Life Science, Inc. $20.0306/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252294917 CMS
ARGENX US, INC. $600.0005/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240428194 CMS
Lundbeck LLC $99.6605/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251861415 CMS
PFIZER INC. $10.3405/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231714416 CMS
EMD Serono, Inc. $25.2905/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236906195 CMS
Lilly USA, LLC $117.0105/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186839861 CMS
Teva Pharmaceuticals USA, Inc. $26.5805/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247551355 CMS
Alexion Pharmaceuticals, Inc. $28.2105/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202953852 CMS
Amgen Inc. $25.0205/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228336074 CMS
ARGENX US, INC. $124.6905/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240428262 CMS
Lilly USA, LLC $19.5405/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186783871 CMS
UCB, Inc. $1,050.0005/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224529218 CMS
TG Therapeutics, Inc. $30.3805/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226206361 CMS
PFIZER INC. $10.8905/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231726812 CMS
Biogen, Inc. $17.6305/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208346769 CMS
UCB, Inc. $43.1505/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224529216 CMS
Alexion Pharmaceuticals, Inc. $24.7905/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202939920 CMS
ANI Pharmaceuticals, Inc. $32.3105/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248616501 CMS
ABBVIE INC. $24.2805/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204810620 CMS
Biogen, Inc. $31.0805/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208319764 CMS
PFIZER INC. $21.0905/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228893895 CMS
ABBVIE INC. $33.2105/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204810616 CMS
Janssen Biotech, Inc. $20.9105/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174910697 CMS
Alexion Pharmaceuticals, Inc. $20.3805/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202985974 CMS
Novartis Pharmaceuticals Corporation $29.0805/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200415863 CMS
ABBVIE INC. $23.7804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204810612 CMS
ARGENX US, INC. $1,600.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1240424834 CMS
PFIZER INC. $16.7004/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231297408 CMS
SK Life Science, Inc. $20.8904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252294897 CMS
Amgen Inc. $2.3904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227104346 CMS
Teva Pharmaceuticals USA, Inc. $26.0904/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247551337 CMS
UCB, Inc. $33.4204/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224529214 CMS
PFIZER INC. $9.0404/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228982506 CMS
ANI Pharmaceuticals, Inc. $15.6504/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248644775 CMS
GENZYME CORPORATION $124.6904/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233588331 CMS
Biogen, Inc. $24.5804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208377301 CMS
Alexion Pharmaceuticals, Inc. $27.2404/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202970920 CMS
Janssen Biotech, Inc. $105.2204/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174911193 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,021.91 86
PY2020 $9,578.69 24
PY2021 $6,449.98 20
PY2022 $22,136.92 93
PY2023 $36,030.87 197
PY2024 $27,400.48 226
PY2025 $57,085.34 294

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,905.19 8
PY2025 Principal investigator $53,541.80 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202533775
Principal investigator 1 Ipsen Innovation $2,343.00 12/23/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301889
Principal investigator 1 ABBVIE INC. $2,413.00 12/04/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202528032
Principal investigator 1 Ipsen Innovation $745.80 12/01/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301891
Principal investigator 1 ABBVIE INC. $605.00 11/04/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202521083
Principal investigator 1 Ipsen Innovation $745.80 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301869
Principal investigator 1 Ipsen Innovation $745.80 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301871
Principal investigator 1 Ipsen Innovation $745.80 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301873
Principal investigator 1 Ipsen Innovation $3,260.40 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301875
Principal investigator 1 Ipsen Innovation $1,914.00 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301877
Principal investigator 1 Ipsen Innovation $3,260.40 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301879
Principal investigator 1 Ipsen Innovation $2,343.00 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301881
Principal investigator 1 Ipsen Innovation $745.80 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301883
Principal investigator 1 Ipsen Innovation $3,260.40 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301885
Principal investigator 1 Ipsen Innovation $2,343.00 10/22/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301887
Principal investigator 1 Alexion Pharmaceuticals, Inc. $429.00 10/14/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH, LLC
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185537317
Principal investigator 1 ABBVIE INC. $1,745.00 10/09/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202514211
Principal investigator 1 ABBVIE INC. $1,745.00 09/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202507819
Principal investigator 1 ABBVIE INC. $1,210.00 08/05/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202501614
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301843
Principal investigator 1 Ipsen Innovation $2,145.00 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301845
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301847
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301849
Principal investigator 1 Ipsen Innovation $1,914.00 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301851
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301853
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301855
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301857
Principal investigator 1 Ipsen Innovation $1,914.00 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301859
Principal investigator 1 Ipsen Innovation $2,145.00 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301861
Principal investigator 1 Ipsen Innovation $745.80 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301863
Principal investigator 1 Ipsen Innovation $1,848.00 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301865
Principal investigator 1 Ipsen Innovation $2,310.00 07/30/2025 Non-covered Recipient Entity
Advanced Neurosciences Research, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184301867
Principal investigator 1 ABBVIE INC. $4,240.00 07/02/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202495003
Principal investigator 1 ABBVIE INC. $605.00 06/03/2025 Non-covered Recipient Entity
ADVANCED NEUROSCIENCES RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202488599
Recipient Merck Healthcare KGaA $154.61 05/15/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192553
Recipient Merck Healthcare KGaA $607.94 04/25/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192541
Recipient Merck Healthcare KGaA $39.00 04/25/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192543
Recipient Merck Healthcare KGaA $30.00 04/25/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192547
Recipient Merck Healthcare KGaA $45.00 04/24/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192545
Recipient Merck Healthcare KGaA $30.00 04/24/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192551
Recipient Merck Healthcare KGaA $777.35 04/23/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192549
Recipient Merck Healthcare KGaA $221.29 04/23/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1241192555